

Table 36. Culture-Positive Tuberculosis Cases and Percentages with Drug-Susceptibility Results, by Resistance to INH or Multidrug Resistance: Reporting Areas, 2005

Reporting Area	Total Culture Positive Cases	Cases with Initial Drug-Susceptibility Testing Performed ¹		Resistance ²			
				Isoniazid ¹		Isoniazid and Rifampin ³	
		No.	(%)	No.	(%)	No.	(%)
United States	10,943	10,355	(94.6)	804	(7.8)	121	(1.2)
Alabama	165	158	(95.8)	9	(5.7)	0	(0.0)
Alaska	54	54	(100.0)	4	(7.4)	0	(0.0)
Arizona	206	162	(78.6)	21	(13.0)	1	(0.6)
Arkansas	71	63	(88.7)	3	(4.8)	0	(0.0)
California	2,282	2,142	(93.9)	208	(9.7)	33	(1.5)
Colorado	69	69	(100.0)	3	(4.3)	0	(0.0)
Connecticut	80	79	(98.8)	7	(8.9)	0	(0.0)
Delaware	23	23	(100.0)	0	(0.0)	0	(0.0)
District of Columbia	51	51	(100.0)	5	(9.8)	3	(6.0)
Florida	850	813	(95.6)	65	(8.0)	10	(1.2)
Georgia	397	389	(98.0)	22	(5.7)	1	(0.3)
Hawaii	89	84	(94.4)	3	(3.6)	0	(0.0)
Idaho	19	16	(84.2)	1	(6.3)	0	(0.0)
Illinois	450	412	(91.6)	28	(6.8)	0	(0.0)
Indiana	118	118	(100.0)	8	(6.8)	1	(0.8)
Iowa	40	40	(100.0)	3	(7.5)	0	(0.0)
Kansas	46	38	(82.6)	1	(2.6)	0	(0.0)
Kentucky	111	107	(96.4)	4	(3.7)	1	(0.9)
Louisiana	199	148	(74.4)	—	—	—	—
Maine	10	9	(90.0)	0	(0.0)	0	(0.0)
Maryland	221	218	(98.6)	19	(8.7)	0	(0.0)
Massachusetts	192	188	(97.9)	22	(11.7)	7	(3.7)
Michigan	200	195	(97.5)	10	(5.1)	1	(0.5)
Minnesota	150	150	(100.0)	14	(9.3)	4	(2.7)
Mississippi	88	80	(90.9)	3	(3.8)	0	(0.0)
Missouri	89	83	(93.3)	4	(4.8)	1	(1.2)
Montana	9	9	(100.0)	1	(11.1)	0	(0.0)
Nebraska	32	32	(100.0)	3	(9.4)	0	(0.0)
Nevada	92	88	(95.7)	6	(6.8)	0	(0.0)
New Hampshire	4	4	(100.0)	0	(0.0)	0	(0.0)
New Jersey	387	380	(98.2)	40	(10.5)	10	(2.6)
New Mexico	34	34	(100.0)	5	(14.7)	0	(0.0)
New York State ²	238	237	(99.6)	21	(8.9)	3	(1.3)
New York City	751	701	(93.3)	74	(10.6)	22	(3.1)
North Carolina	271	261	(96.3)	22	(8.4)	3	(1.1)
North Dakota	4	4	(100.0)	0	(0.0)	0	(0.0)
Ohio	188	188	(100.0)	9	(4.8)	1	(0.5)
Oklahoma	88	88	(100.0)	5	(5.7)	1	(1.1)
Oregon	86	86	(100.0)	5	(5.8)	0	(0.0)
Pennsylvania	270	224	(83.0)	17	(7.6)	2	(0.9)
Rhode Island	19	19	(100.0)	1	(5.3)	0	(0.0)
South Carolina	183	179	(97.8)	8	(4.5)	3	(1.7)
South Dakota	14	14	(100.0)	1	(7.1)	0	(0.0)
Tennessee	239	226	(94.6)	14	(6.2)	2	(0.9)
Texas	1,159	1,135	(97.9)	45	(4.0)	4	(0.4)
Utah	21	21	(100.0)	0	(0.0)	0	(0.0)
Vermont	6	6	(100.0)	0	(0.0)	0	(0.0)
Virginia	275	233	(84.7)	17	(7.3)	2	(0.9)
Washington	208	203	(97.6)	26	(12.8)	3	(1.5)
West Virginia	28	27	(96.4)	3	(11.1)	0	(0.0)
Wisconsin	67	67	(100.0)	10	(14.9)	2	(3.0)
Wyoming	0	0	—	—	—	—	—
American Samoa ³	4	4	(100.0)	0	(0.0)	0	(0.0)
Fed. States of Micronesia ³	21	18	(85.7)	1	(5.6)	1	(5.6)
Guam ³	39	35	(89.7)	4	(11.4)	1	(2.9)
Marshall Islands ³	46	45	(97.8)	1	(2.2)	0	(0.0)
N. Mariana Islands ³	25	18	(72.0)	—	—	—	—
Puerto Rico ³	99	94	(94.9)	2	(2.1)	0	(0.0)
Republic of Palau ³	3	3	(100.0)	0	(0.0)	0	(0.0)
U.S. Virgin Islands ³

¹Patients tested to at least isoniazid

²Isolates may be resistant to other drugs. Overall U.S. percentage based on 52 reporting areas (50 states, New York City, and the District of Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.

³Patients tested to at least isoniazid and rifampin

⁴Excludes New York City.

⁵Not included in U.S. totals.

Note: Ellipses indicate data not available.